Utilizing the adjuvant properties of CD1d-depenclent NKT cells in T cell-mediated immunotherapy

Journal of Clinical Investigation

Volumn 114, Issue 12, 2004, Pages 1800-1811

  Silk, Jonathan D ^a   Hermans, Ian F ^a   Gileadi, Uzi ^a   Chong, Tsung Wen ^a   Shepherd, Dawn ^a   Salio, Mariolina ^a   Mathew, Bini ^b   Schmidt, Richard R ^b   Lunt, Sarah Jane ^c   Williams, Kaye J ^c   Stratford, Ian J ^c   Harris, Adrian L ^a   Cerundolo, Vincenzo ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ANTIGEN; CD1D ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; GLYCOLIPID; HLA A2 ANTIGEN; IMMUNOLOGICAL ADJUVANT; LIGAND; NY ESO 1 ANTIGEN; PEPTIDE; PROTEIN; SPHINGOSINE; TOLL LIKE RECEPTOR 4; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CD1 ANTIGEN; CD86 ANTIGEN; CD86 PROTEIN, MOUSE; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VIVO STUDY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STIMULATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION; ANIMAL; BIOSYNTHESIS; C3H MOUSE; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL SEPARATION; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE; MUTATION; PHENOTYPE; PROMOTER REGION; SPLEEN; TIME; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD1; ANTIGENS, CD86; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CULTURE MEDIA; DENDRITIC CELLS; EPITOPES; FLOW CYTOMETRY; HLA-A2 ANTIGEN; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PHENOTYPE; PROMOTER REGIONS (GENETICS); RECEPTORS, CELL SURFACE; SPLEEN; T-LYMPHOCYTES; TIME FACTORS; TOLL-LIKE RECEPTORS;

EID: 15244351558     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200422046     Document Type: Article

References (58)

1. Boon, T., and Old, L.J. 1997. Cancer tumor antigens. Curr. Opin. Immunol. 9:681-683.
2. Jager, E., et al. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptideepitopes. J. Exp. Med. 187:265-270.
3. Ramshaw, I.A., and Ramsay, A.J. 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today. 21:163-165.
4. Hanke, T., et al. 1999. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:7524-7532.
5. McConkey, S.J., et al. 2003. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9:729-735.
6. Palmowski, M.J., et al. 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168:4391-4398.
7. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
8. Conry, R.M., et al. 2002. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res. 8:2782-2787.
9. Wang, R., et al. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:476-480.
10. Hsu, F.J., et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
11. Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., and Falo, L.D., Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283-287.
12. Cerundolo, V., Hermans, I.P., and Salio, M. 2004. Dendritic cells: a journey from laboratory to clinic. Nat. Immunol. 5:7-10.
13. Medzhitov, R., and Janeway, C., Jr. 2000. The Toll receptor family and microbial recognition. Trends Microbiol. 8:452-456.
14. Leslie, D.S., et al. 2002. CD1-mediated γ/δ T cell maturation of dendritic cells. J. Exp. Med. 196:1575-1584.
15. Vincent, M.S., et al. 2002. CD1-dependent dendritic cell instruction. Nat. Immunol. 3:1163-1168.
16. + cells: new clues to their origin, specificity, and function. J. Exp. Med. 182:633-638.
17. - T cells in mice and humans. J. Exp. Med. 180:1097-1106.
18. Kawano. T., et al. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science. 278:1626-1629.
19. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171:5140-5147.
20. Fujii, S., Shimizu, K., Smith, C, Bonifaz, L., and Steinman, R.M. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198:267-279.
21. Fujii, S., Liu, K., Smith, C., Bonito, A.J., and Steinman, R.M. 2004. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligacion in addition to antigen presentation and CD80/86 costiinulatron. J. Exp. Med. 199:1607-1618.
22. Sporri, R., and Reis e Sousa, C. 2003. Newly activated T cells promote maturation of bystander dendritic cells but not IL-12 production. J. Immunol. 171:6406-6413.
23. +NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J. Immunol. 163:93-101.
24. Poltorak, A., et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 282:2085-2088.
25. Qureshi, N., Takayama, K., and Ribi, E. 1982. Purification and structural determination of non toxic hpid A obtained from the lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem. 257:11808-11815.
26. Montoya, M., et al. 2002. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood. 99:3263-3271.
27. Miyamoto, K., Miyake, S., and Yamaimira, T. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 413:531-534.
28. Brigl, M., Bry, L., Kent, S.C., Gumperz, J.E., and Brenner, M.B. 2003. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4:1230-1237.
29. Chen, J.L., et al. 2000. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 165:948-955.
30. Matsuda, J.L., et al. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192:741-754.
31. Chaliacombe, S.J., and Tomasi, T.B., Jr. 1980. Systemic tolerance and secretory immunity after oral immunization. J. Exp. Med. 152:1459-1472.
32. Chen, Y., et al. 1995. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 376:177-180.
33. Hermans, I.F., et al. 2004. The VITAL assay: a versacile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J. Immunol. Methods. 285:25-40.
34. Yang, Y., Huang, C.T., Huang, X., and Pardoll, D.M. 2004. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5:508-515.
35. Rock, K.L., Gamble, S., and Rothstein, L. 1990. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science. 249:918-921.
36. Sevan, M.J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do nor cross-react in the cytoroxic assay. J. Exp. Med. 143:1283-1288.
37. Carbone, F.R., and Bevan, M.J. 1990. Class I-rescricced processing and presentation of exogenous cell-associared antigen in vivo. J. Exp. Med. 171:377-387.
38. Zinkernagel, R.M. 2002. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 32:2385-2392.
39. + T cells in vivo. J. Immunol. 170:2540-2548.
40. Ruegg, C., et al. 1998. Evidence for the involvement of endothelial cell integhn αVβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat. Med. 4:408-414.
41. Coughlin, C.M., et al. 1998. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity. 9:25-34.
42. Fujii, S., Shimizu, K., Kronenberg, M., and Steinman, R.M. 2002. Prolonged IFN-γ-producing NKT response induced with α- galactosylcetamide-loaded DCs. Nat. Immunol. 3:867-874.
43. Strobel, S., and Mowat, A.M. 1998. Immune responses to dietary antigens: oral tolerance. Immunol. Today. 19:173-181.
44. Gallery, M.P., Kamei, T., and Flye, M.W. 1989. The effect of portacaval shunt on delayed-hypersensitivity responses following antigen feeding. J. Surg. Res. 46:391-394.
45. Callery, M.P., Kamei, T., and Flye, M.W. 1989. Kupffer cell blockade inhibits induction of tolerance by the porral venous roure. Transplantation. 47:1092-1094.
46. Knolle, P.A., and Limmer, A. 2003. Conrrol of immune responses by scavenger liver endothelial cells. Swiss Med. Wkly. 133:501-506.
47. + T cells results in antigen-specific T-cell tolerance. Nat. Med. 6:1348-1354.
48. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood. 103:383-389.
49. Giaccone, G., et al. 2002. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8:3702-3709.
50. Taniguchi, M., et al. 1996. Essential requirement of an invariant Vα14 T cell antigen receptor expression in rhe development of natural killer T cells. Proc. Natl. Acad. Sci. U. S. A. 93:11025-11028.
51. Smiley, S.T., Kaplan, M.H., and Grusby, M.J. 1997. Immunoglobulin E production in the absence of interleukin-4-secreting CDI-dependent cells. Science. 275:977-979.
52. Vitiello, A., Marchesini, D., Furze, J., Sherman, L.A., and Chesnut, R. W. 1991. Analysis of rhe HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1007-1015.
53. Huang, S., et al. 1993. Immune response in mice that lack the interferon-γ receptor. Science. 259:1742-1745.
54. Muller, U., et al. 1994. Functional role of type I and type II interferons in antiviral defense. Science. 264:1918-1921.
55. Moore, M.W., Carbone, F.R., and Bevan, M.J. 1988. Introduction of soluble protein into rhe class I pathway of antigen processing and presentation. Cell. 54:777-785.
56. Overwijk, W.W., Surman, D.R., Tsung, K., and Restifo, N.P. 1997. Identification of a Kb-restricted CTL epitope of β-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 12:117-123.
57. Figueroa-Perez, S., and Schmidt, R.R. 2000. Total synthesis of α-galactosyl cerebroside. Carbohydr. Res. 328:95-102.
58. Whelan, J.A., et al. 1999. Specificity of CTL interactions with peptide-MHC class 1 tetrameric complexes is temperature dependent. J. Immunol. 163:4342-4348.